BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernández F, Blanquer A, Linares M, López A, Tarín F, Cerveró A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol. 1998;99:217-220. [PMID: 9644300 DOI: 10.1159/000040842] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Masood I, Rafiq A, Majid Z. Hepatitis E presenting with thrombocytopaenia. Trop Doct 2014;44:219-20. [PMID: 24472742 DOI: 10.1177/0049475514521610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
2 Tampaki M, Koskinas J. Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol. 2014;20:12372-12380. [PMID: 25253938 DOI: 10.3748/wjg.v20.i35.12372] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 2006;8:53-9. [PMID: 16510035 DOI: 10.1007/s11894-006-0064-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
4 Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin. 2005;21:563-587. [PMID: 15992673 DOI: 10.1016/j.ccc.2005.03.002] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
5 Ayesh (Haj Yousef) MH, Alawneh KM. <i>Candida albicans</i>-Induced Chronic Thrombocytopenic Purpura. Acta Haematol 2011;126:202-4. [DOI: 10.1159/000329901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Danish FI, Yasmin S. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia. Hepat Med 2013;5:17-30. [PMID: 24696622 DOI: 10.2147/HMER.S27100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004;19:357-81. [PMID: 15554428 DOI: 10.1023/b:mebr.0000043982.17294.9b] [Cited by in Crossref: 81] [Cited by in F6Publishing: 24] [Article Influence: 5.1] [Reference Citation Analysis]
8 Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-4207. [PMID: 21325604 DOI: 10.1182/blood-2010-08-302984] [Cited by in Crossref: 1130] [Cited by in F6Publishing: 798] [Article Influence: 113.0] [Reference Citation Analysis]
9 Varma S, Kumar S, Garg A, Malhotra P, Das A, Sharma A, Chawla YK, Dhiman RK. Hepatitis C virus infection among patients with chronic immune thrombocytopenic purpura in northern India. J Clin Exp Hepatol 2011;1:68-72. [PMID: 25755317 DOI: 10.1016/S0973-6883(11)60124-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Silva GF, Grotto RM, Verdichio-Moraes CF, Corvino SM, Ferrasi AC, Silveira LV, Pardini MI. Human platelet antigen genotype is associated with progression of fibrosis in chronic hepatitis C. J Med Virol 2012;84:56-60. [PMID: 22095535 DOI: 10.1002/jmv.22191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
11 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1177/096120330501400114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
12 Dai CY, Ho CK, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML, Chuang WL. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2010;52:160-166. [PMID: 20034694 DOI: 10.1016/j.jhep.2009.11.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
13 Liebman HA. Viral-Associated Immune Thrombocytopenic Purpura. Hematology 2008;2008:212-8. [DOI: 10.1182/asheducation-2008.1.212] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
14 Lebano R, Rosato V, Masarone M, Romano M, Persico M. The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Res Notes 2014;7:59. [PMID: 24457056 DOI: 10.1186/1756-0500-7-59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, Takamori H, Kanemitsu K, Hirota M, Baba H. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol. 2007;22:1638-1642. [PMID: 17683504 DOI: 10.1111/j.1440-1746.2007.05090.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
16 Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818-824. [PMID: 15953010 DOI: 10.1111/j.1365-2141.2005.05542.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
17 Sheehan VA, Weir A, Waters B. Hepatitis C and neutropenia: . Current Opinion in Hematology 2014;21:58-63. [DOI: 10.1097/moh.0000000000000006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75:417-423. [PMID: 16191092 DOI: 10.1111/j.1600-0609.2005.00524.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
19 Sekiguchi T, Nagamine T, Takagi H, Mori M. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol 2006;12:1205-10. [PMID: 16534872 DOI: 10.3748/wjg.v12.i8.1205] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017;9:e2017019. [PMID: 28293407 DOI: 10.4084/mjhid.2017.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
21 Ando M, Iwamoto Y, Suda A, Tsuchiya K, Nihei H. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood 2001;97:915-21. [DOI: 10.1182/blood.v97.4.915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
22 Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology. 2003;37:1267-1276. [PMID: 12774004 DOI: 10.1053/jhep.2003.50209] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
23 Elefsiniotis IS, Pantazis KD, Fotos NV, Moulakakis A, Mavrogiannis C. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:622-623. [PMID: 16638114 DOI: 10.1111/j.1440-1746.2006.03418.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
24 Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol. 2005;78:138-141. [PMID: 15682410 DOI: 10.1002/ajh.20270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
25 D’alteroche L, Assor P, Lefrou L, Senecal D, Gaudy C, Bacq Y. Neutropénie et thrombopénie auto-immunes sévères associées à une hépatite chronique C : effet du traitement antiviral. Gastroentérologie Clinique et Biologique 2005;29:297-9. [DOI: 10.1016/s0399-8320(05)80766-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
26 Zhang L, Li H, Zhao H, Ji L, Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol. 2003;70:196-197. [PMID: 12605667 DOI: 10.1034/j.1600-0609.2003.00032.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
27 Shao LN, Zhang ST, Wang N, Yu WJ, Chen M, Xiao N, Duan Y, Pan LZ, Song WQ, Xia YX, Zhang L, Qi N, Liu M, Zhou SH. Platelet indices significantly correlate with liver fibrosis in HCV-infected patients. PLoS One. 2020;15:e0227544. [PMID: 31917827 DOI: 10.1371/journal.pone.0227544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Abdelmalek MF, Hellner LB, Zumberg M, Melgen VW, Lottenberg R. Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection. Dig Dis Sci 2007;52:914-9. [PMID: 17347887 DOI: 10.1007/s10620-006-9319-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Mousa SM. Hepatitis C among Egyptian Patients Referred for Bone Marrow Examination: Seroprevalence and Analysis of Hematological Findings. Bone Marrow Res 2014;2014:549716. [PMID: 24818027 DOI: 10.1155/2014/549716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Panzer S, Seel E, Brunner M, Körmöczi GF, Schmid M, Ferenci P, Peck-Radosavljevic M. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol. 2006;77:513-517. [PMID: 17042765 DOI: 10.1111/j.0902-4441.2006.t01-1-ejh2888.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
31 de Almeida AJ, Campos-de-Magalhães M, Antonietti CL, Brandão-Mello CE, da Silva ML, de Oliveira RV, do Espírito-Santo MP, Yoshida CF, Lampe E. Autoimmune thrombocytopenia related to chronic hepatitis C virus infection. Hematology 2009;14:49-58. [PMID: 19154665 DOI: 10.1179/102453309X385106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Dufour JF, Pradat P, Ruivard M, Hot A, Dumontet C, Broussolle C, Trepo C, Sève P. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol. 2009;21:245-253. [PMID: 19279468 DOI: 10.1097/meg.0b013e3283249908] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040-2045. [PMID: 12190174 DOI: 10.1111/j.1572-0241.2002.05845.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.3] [Reference Citation Analysis]
34 Gangireddy VG, Kanneganti PC, Sridhar S, Talla S, Coleman T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014;28:558-564. [PMID: 25222481 DOI: 10.1155/2014/532191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
35 Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol 2017;10:99-106. [PMID: 27936979 DOI: 10.1080/17474086.2017.1271319] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
36 Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura: . Current Opinion in Hematology 2007;14:557-73. [DOI: 10.1097/moh.0b013e3282ab9904] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
37 Arena R, Cecinato P, Lisotti A, Buonfiglioli F, Calvanese C, Grande G, Montagnani M, Azzaroli F, Mazzella G. Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature. World J Hepatol 2015;7:1718-22. [PMID: 26140092 DOI: 10.4254/wjh.v7.i12.1718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Handa A, Brown KE. GB virus C/hepatitis G virus replicates in human haematopoietic cells and vascular endothelial cells. Journal of General Virology 2000;81:2461-9. [DOI: 10.1099/0022-1317-81-10-2461] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
39 Karakan T, Cindoruk M, Degertekin B, Dogan I, Sancak A, Dumlu S, Gorgul A, Unal S. Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia. Curr Ther Res Clin Exp 2005;66:247-53. [PMID: 24764593 DOI: 10.1016/j.curtheres.2005.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Sakuraya M, Murakami H, Uchiumi H, Hatsumi N, Akiba T, Yokohama A, Matsushima T, Tsukamoto N, Morita K, Karasawa M. Steroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection. Eur J Haematol. 2002;68:49-53. [PMID: 11952821 DOI: 10.1034/j.1600-0609.2002.00509.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
41 Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68:202-209. [PMID: 11754404 DOI: 10.1002/ajh.1180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
42 Pugliese A, Gennero L, Cutufia M, Enrietto M, Morra E, Pescarmona P, Ponzetto A. HCV infective virions can be carried by human platelets. Cell Biochem Funct 2004;22:353-8. [DOI: 10.1002/cbf.1113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
43 Stasi R, Chia LW, Kalkur P, Lowe R, Shannon MS. Pathobiology and treatment of hepatitis virus-related thrombocytopenia. Mediterr J Hematol Infect Dis 2009;1:e2009023. [PMID: 21415958 DOI: 10.4084/MJHID.2009.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
44 Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44:S24-S34. [PMID: 18096469 DOI: 10.1053/j.seminhematol.2007.11.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
45 Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis. 2004;39:790-796. [PMID: 15472809 DOI: 10.1086/423384] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
46 Jiménez‐sáenz M, Rojas M, Piñar A, Salas E, Rebollo J, Carmona I, Herrerías‐esteban JM, Herrerías‐gutiérrez JM. Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to α ‐interferon. Journal of Gastroenterology and Hepatology 2001;15:567-9. [DOI: 10.1046/j.1440-1746.2000.02155.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
47 Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1275-1297. [PMID: 19932434 DOI: 10.1016/j.hoc.2009.08.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
48 Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol 2010;16:51-6. [PMID: 20065578 DOI: 10.4103/1319-3767.58772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
49 Andemariam B, Psaila B, Bussel JB. Novel Thrombopoietic Agents. Hematology 2007;2007:106-13. [DOI: 10.1182/asheducation-2007.1.106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
50 Calvaruso V, Craxì A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol. 2013;19:8916-8923. [PMID: 24379616 DOI: 10.3748/wjg.v19.i47.8916] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
51 Ghalib R, Levine C, Hassan M, McClelland T, Goss J, Stribling R, Seu P, Patt YZ. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology. 2003;37:1165-1171. [PMID: 12717398 DOI: 10.1053/jhep.2003.50160] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
52 Lövy MR, Starkebaum G. Rheumatic disorders associated with hepatitis C. Best Practice & Research Clinical Rheumatology 2000;14:535-57. [DOI: 10.1053/berh.2000.0092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
53 Stasi R. Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias. Semin Hematol 2009;46:S15-25. [PMID: 19245929 DOI: 10.1053/j.seminhematol.2008.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
54 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1191/0961203305lu2122oa] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Cheney CP, Chopra S, Graham C. Hepatitis C. Infect Dis Clin North Am 2000;14:633-67. [PMID: 10987114 DOI: 10.1016/s0891-5520(05)70125-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
56 Wong EY, Rose MG. Why does my patient have thrombocytopenia? Hematol Oncol Clin North Am 2012;26:231-52, vii. [PMID: 22463825 DOI: 10.1016/j.hoc.2012.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
57 Ramos-Casals M, García-Carrasco M, López-Medrano F, Trejo O, Forns X, López-Guillermo A, Muñoz C, Ingelmo M, Font J. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003;82:87-96. [PMID: 12640185 DOI: 10.1097/00005792-200303000-00003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.1] [Reference Citation Analysis]